Highlights Articles

Microbiomes modulate the local immune response, influencing immunotherapy response and toxicity
Immunotherapy has revolutionized the treatment of several cancers. However, it remains elusive why only some patients benefit from these treatments and why some patients experience immune-related adverse events (irAEs). More

Microbiomes modulate the local immune response, influencing immunotherapy response and toxicity

Sep 6, 2023 | , ,

Immunotherapy has revolutionized the treatment of several cancers. However, it remains elusive why only some patients...

read more
Resistance to anti-PD-1 immunotherapy can be attributed to the gut microbiome
Immunotherapies (Immune Checkpoint Inhibitors, ICI) have become a powerful therapeutic strategy for treating a variety of cancers. It is a very exciting area, but with challenges. Indeed, the patients’ response to these therapies is often heterogeneous and not durable, with only 20 to 40% of patients actually responding. More

Resistance to anti-PD-1 immunotherapy can be attributed to the gut microbiome

Jun 23, 2023 | , ,

Immunotherapies (Immune Checkpoint Inhibitors, ICI) have become a powerful therapeutic strategy for treating a variety...

read more
Mouse models with human microbiome
Vaiomer and Physiogenex are proud to announce the launch of the TRANSBIOTIC project, to develop and validate mouse models with human microbiomes for evaluating therapies targeting metabolic and inflammatory diseases. Thanks La Région Occitanie-Pyrénées-Méditerranée for its support !

Mouse models with human microbiome

Apr 27, 2023 | ,

Physiogenex and Vaiomer Launch the TRANSBIOTIC project: A New Collaborative Research Project on mouse models...

read more